Related Experiment Video
Updated: Feb 16, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
The implication from RAS/RAF/ERK signaling pathway increased activation in epirubicin treated triple negative breast
Jianbo Huang1, Qingqing Luo1, Yun Xiao2
1Department of Endocrine & Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Background:
Triple negative breast cancer (TNBC) is not sensitive to RAS/RAF/ERK signaling pathway (ERK pathway) targeting therapy, due to the absence of excessive activation of ERK pathway. However, the kinase cascades might be activated after chemotherapy in TNBC. Here we aimed to predict whether ERK pathway targeting therapy could be used as an adjuvant therapy in TNBC.
Methods:
Within online GEO datasets (GSE43816 and GSE54326), gene set enrichment analysis (GSEA) was performed to detect molecular changes in epirubicin treated TNBC samples and cells, ERK pathway components and regulation genes changes were included.
Results:
In epirubicin treated TNBC samples and cells, we found ERK pathway components (eg. MAPK13, MAP3K1, MAPK12, MAPK11 and MAPKAPK3) were obviously enriched, also, expression of ERK pathway positive regulation genes significantly increased (P<0.05) and negative regulation genes decreased (P<0.05) in epirubicin resistant cells. Moreover, phosphorylated ERK levels were significantly elevated in MDA-MB-231 cells after epirubicin treatment.
Conclusion:
ERK signaling pathway was more activated in epirubicin treated TNBC, possibly contributing to the epirubicin resistance in TNBC, it implicated that ERK pathway could be used as an novel candidate for targeting therapy in refractory and relapse TNBC.
Insights
Chemotherapy may activate the ERK pathway in triple negative breast cancer (TNBC), potentially driving resistance. Targeting this pathway could offer new treatment options for refractory TNBC.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Triple negative breast cancer (TNBC) typically lacks sensitivity to ERK pathway inhibitors.
- Chemotherapy may induce kinase cascade activation in TNBC, altering treatment response.
Purpose of the Study:
- To investigate the potential of ERK pathway targeting therapy as an adjuvant treatment for TNBC.
- To determine if chemotherapy activates the ERK pathway in TNBC.
Main Methods:
- Gene set enrichment analysis (GSEA) of online datasets (GSE43816, GSE54326) from epirubicin-treated TNBC samples and cells.
- Analysis of ERK pathway components and regulatory gene expression changes.
Main Results:
- Enrichment of ERK pathway components (e.g., MAPK13, MAP3K1) observed in epirubicin-treated TNBC.
- Increased expression of positive and decreased expression of negative ERK pathway regulators in resistant cells.
- Elevated phosphorylated ERK levels in MDA-MB-231 cells post-epirubicin treatment.
Conclusions:
- The ERK signaling pathway is activated by epirubicin treatment in TNBC, potentially contributing to drug resistance.
- Targeting the ERK pathway presents a novel therapeutic strategy for refractory and relapsed TNBC.
Related Concept Videos
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
Hedgehog Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The Ras Gene
Ras is a...
Non-Canonical Wnt Signaling Pathways
Canonical Wnt Signaling Pathway

